EMA Guides On Early Access Schemes A 'Considerable Improvement', But More Clarity Needed
This article was originally published in SRA
Executive Summary
The latest revisions to the European Medicines Agency's guidance documents on the agency's conditional marketing authorization and accelerated access pathways represent a 'considerable improvement' over the previous guidances, but some points still require further clarification, says EU pharma industry federation EFPIA.